```json
{
  "filename": "awiqli-epar-product-information_en.pdf",
  "Document Type": "Summary of Product Characteristics",
  "Product Name": "Awiqli",
  "Active Substance(s)": "insulin icodec",
  "Strength": "700 units/mL",
  "Pharmaceutical Form": "solution for injection; solution for injection in pre -filled pen",
  "Route of Administration": "subcutaneous",
  "Indications": "Treatment of diabetes mellitus in adults.",
  "Posology": "basal insulin for once -weekly subcutaneous administration; to be administered  on the same day of the week; In patients with type 1 diabetes mellitus, this medicinal product must be combined with bolus insulin to cover mealtime insulin requirements.; In patients with type 2 diabetes mellitus, this medicinal product can be administered alone or in any combination with oral antidiabetic medicinal products, GLP -1 receptor agonists and bolus insulin.; recommended weekly starting dose is 70  units and followed by individual once -weekly dose adjustments; Awiqli  dose when switching from once- or twice-daily basal insulin for type 2 diabetes and type 1 diabetes patients , in case initially (week 1) a one -time additional dose is administered: Week 1b 1.5 x previous total daily basal insulin dose multiplied by 7 . One -time additional dose given in week 1 is recommended if seeking faster achievement of glycaemic control in type 2 diabetes patients . For type 1 diabetes patients, this dose is always recommended; Week 2c previous total daily basal insulin dose multiplied by 7",
  "Contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1",
  "Special Warnings and Precautions": "Hypoglycaemia; Hyperglycaemia; Switching a patient between another insulin medicinal product  and insulin icodec  should be done under medical supervision and may result in the need for a change in dosage (see section 4.2); Medication errors can occur in the form of e.g. , overdose, dosing errors or forgetting to remove the recommended one -time additional dose after the first injection; Lipodystrophy and cutaneous amyloidosis; Eye disorder; Avoidance of medication errors; Immunogenicity; Combination of pioglitazone and insulin medicinal products",
  "Marketing Authorisation Holder": "Novo Nordisk A/S",
  "Marketing Authorisation Number": "EU/1/24/1815/001; EU/1/24/1815/002; EU/1/24/1815/003; EU/1/24/1815/004; EU/1/24/1815/005; EU/1/24/1815/006; EU/1/24/1815/007; EU/1/24/1815/008; EU/1/24/1815/009; EU/1/24/1815/010; EU/1/24/1815/011; EU/1/24/1815/012; EU/1/24/1815/013; EU/1/24/1815/014",
  "Date of First Authorisation": "17 May 2024",
  "Date of Latest Renewal": "Not found",
  "Shelf Life": "3 years; After first opening or carried as a spare, the medicinal product may be stored for a maximum of 12 weeks.",
  "Storage Conditions": "Before first use Store in a refrigerator (2  °C - 8 °C). Do not freeze. Keep away from the freezing element. Keep the cap on the pen in order to protect from light.; After first opening or if carried as a spare For storage conditions after first opening of the medicinal product, see section 6.3.",
  "Package Description": "1, 1.5 or 3  mL solution in a cartridge ( type I glass) with a plunger (halobutyl) and a laminated rubber sheet (halobutyl/polyisoprene) contained in a pre -filled multidose disposable pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene.; The pre -filled pen is designed to be used with disposable needles up to a length of 8 mm.; The pen body is in green while the pen label is in darker green with a yellow box highlighting the strength.  The outer packaging is in green with the formulation strength indicated in a yellow -coloured box.",
  "Legal Category": "Medicinal product subject to medical prescription.",
  "ATC Code": "A10AE07",
  "Manufacturers": "Novo Nordisk A/S; Hallas Alle 1, DK-4400 Kalundborg, Denmark; Novo Alle 1, DK-2880 Bagsvaerd Denmark",
  "Excipients": "Glycerol; Metacresol Phenol; Zinc acetate; Sodium chloride; Hydrochloric acid (for pH adjustment); Sodium hydroxide (for pH adjustment); Water for injections"
}
```